BioSpace News Archive

Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe ® Nexus 200™ , expanding its robust endotoxin testing portfolio.

August Bioservices, LLC today announced that it secured $65 million in Series B funding led by Oak HC/FT, who led the Series A in July 2020.

Nemaura Medical, Inc. announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 being held on December 6 – 8, 2022.

Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5).

WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, announced the procurement of additional growth capital as well as changes to executive leadership, including the appointment of Dr. Mark Figgie as Interim Chief Executive Officer.

Rapid Micro Biosystems, Inc., an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced that its Board of Directors has concluded its previously announced review of strategic alternatives.

Kintara Therapeutics, Inc. today announced that Robert E. Hoffman, President and CEO of Kintara, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

DarioHealth Corp., a leader in the global digital therapeutics market, announced that two employers selected Dario as part of an offering from a leading benefits brokerage partner that Dario had previously announced.

bioAffinity Technologies, Inc today announced that David Elzi, Ph.D., bioAffinity Vice President of Research, will discuss his research into a possible mechanism by which the knock down of two genes kills cancer cells with little or no effect on normal cells at Cell Bio, a joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), in Washington, D.C., on Dec. 3-7, 2022.

NLS Pharmaceutics Ltd. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 16/645,306.